DEUTSCHE BANK AG\
BankPosition in GALT — Galectin Therapeutics Inc
CIK 948046
FRANKFURT AM MAIN, 2M
Position in GALT
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$219,949
+$164,798 QoQ
Shares Held
47,403
+86.5% QoQ
Ownership
0.047%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#35
of 98 holders
Holding Since
Mar 2020
6 quarters on record
Voting authority
Sole 1%
Shared 0%
None 99%
Common Shares in GALT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026DEUTSCHE BANK AG\ holds $3,199,137,357 across 296 Biotechnology names. GALT ranks #233 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,579,110 | $784,391,303 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
518,409 | $323,248,743 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
815,400 | $245,459,858 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
888,019 | $166,308,196 | |
| 5 | RPRX |
Royalty Pharma plc
|
2,717,951 | $152,395,510 | |
| 6 | INCY |
Incyte Corp
|
1,262,988 | $143,172,312 | |
| 7 | ARGX |
Argenx SE
|
137,335 | $127,415,291 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
249,611 | $78,899,539 |
All Filings in GALT
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $219,949 | 47,403 | Shares | Defined | 2026-08-07 | |
| 2021-03-31 | $55,151 | 25,416 | Shares | Defined | 2021-05-13 | |
| 2020-12-31 | $61,998 | 27,678 | Shares | Defined | 2021-02-16 | |
| 2020-09-30 | $53,943 | 20,204 | Shares | Defined | 2020-11-12 | |
| 2020-06-30 | $56,328 | 18,408 | Shares | Defined | 2020-08-13 | |
| 2020-03-31 | $27,098 | 13,826 | Shares | Defined | 2020-05-14 | |
| No filing history on record for this holder in this stock. | ||||||